Todas las investigaciones
ReclutamientoFASE3INTERVENCIONISTA

Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia

This important study, called a Phase 3 clinical trial, is looking for people with schizophrenia to test a new medication called KarXT. The main goal is to find out if KarXT can help prevent the symptoms of schizophrenia from returning, or relapsing. Participants will either receive KarXT or a placebo (a dummy pill with no active medicine) to see how well it works and if it's safe. This type of research is crucial for developing new and better treatments to help people manage their condition. All participants will be closely monitored by a medical team.

De un vistazo

Estado
Reclutamiento
Fase
FASE3
Patrocinador
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Objetivo de inscripción
472
Inicio
20 Ago 2026
Estimación de finalización
03 Mar 2029

¿De qué trata este estudio?

This research study is focused on improving treatments for schizophrenia, a long-term mental health condition that affects how a person thinks, feels, and behaves. The study is particularly interested in preventing relapses, which is when symptoms return or get worse after a period of improvement. Preventing relapses is a major goal in managing schizophrenia, as it can significantly impact a person's life and well-being.

The new medicine being tested is called KarXT. Researchers want to compare it to a 'placebo', which is a treatment that looks like the real medicine but contains no active ingredients. This comparison helps scientists understand if KarXT is truly effective and safe. By taking part in such a study, you could contribute to medical knowledge and potentially help others with schizophrenia in the future.

This is a 'Phase 3' study, meaning it's one of the final steps before a new medicine might be considered for general use. These studies are vital for making sure new treatments are both safe and work well for a large number of people before they become widely available.

Puntos clave

  • This study evaluates KarXT, a new medicine for schizophrenia.
  • It aims to prevent symptoms from coming back (relapse prevention).
  • It's a Phase 3 study, a late stage before potential general use.
  • Participants will receive either KarXT or a placebo.
  • Close medical monitoring and regular visits are required.
  • La participación es voluntaria, y puedes retirarte en cualquier momento.

¿Quién puede ser elegible?

To join this study, you need to be an adult between 18 and 65 years old and have been diagnosed with schizophrenia for at least a year. You should have had a hospital stay for schizophrenia sometime in the last year, and currently be experiencing some symptoms, but not severely unwell or in a first-time episode.

There are also some requirements about your current health, such as your body mass index (BMI). You cannot have other significant mental health conditions diagnosed recently, or be at risk of suicidal thoughts. If you've previously had trouble responding to schizophrenia medications or had very long hospital stays recently, you might not be suitable for this study.

The medical team will carefully check all these points to make sure the study is a good and safe fit for everyone involved. They will use specific questionnaires and assessments, like one called PANSS, to confirm you meet the criteria.

¿Podría este estudio ser adecuado para ti?

Responde estas preguntas rápidas para ver si puedes ser elegible. Esto es solo una guía: el equipo de investigación toma la decisión final.

  1. ¿Tienes entre 18 y 65 años?
  2. Have you been diagnosed with schizophrenia for at least a year?
  3. Have you been hospitalised for schizophrenia in the last year?
  4. Do you currently have some schizophrenia symptoms?
  5. Do you have a Body Mass Index (BMI) between 18 and 40?
  6. Have you not had a recent diagnosis of other major mental health conditions?
Responde cada pregunta para ver tu resultado.

¿En qué consiste la participación?

If you decide to take part, you'll be randomly assigned to either receive the new medicine, KarXT, or a placebo (a dummy pill). You won't know which one you're getting, and neither will your study doctor, until the study is over. You'll need to attend regular appointments at the study clinic where you'll have check-ups, assessments, and receive your study medication. These appointments will involve talking about your symptoms, having physical health checks, and possibly blood tests.

The medical team will closely monitor your health and any changes you experience throughout the study. The exact number of visits and the full duration of your participation will be fully explained to you before you make any decisions. There will also be follow-up calls or visits after you stop taking the study medication to see how you are doing.

Riesgos y beneficios potenciales

Taking part in this study could potentially offer some benefits, such as receiving a new investigational treatment that might help your symptoms more effectively than current options, or simply getting very close medical attention during the study. However, there are also potential risks, like experiencing side effects from the medication or the assessments, or not receiving any benefit if you're on the placebo. You'll have a chance to discuss all potential risks and benefits in detail with the study team before agreeing to participate. Remember, your participation is always voluntary, and you have the right to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Locations (59)

  • Pillar Clinical Research - Bentonville
    Código postal verificado
    Bentonville, United States· Reclutamiento
  • Pillar Clinical Research- Little Rock
    Código postal verificado
    Little Rock, Estados Unidos· Reclutamiento
  • Local Institution - 0021
    Código postal verificado
    Little Rock, Estados Unidos· Aún no reclutando
  • Local Institution - 0153
    Código postal verificado
    Rogers, United States· Aún no reclutando
  • Local Institution - 0190
    Código postal verificado
    Anaheim, Estados Unidos· Aún no reclutando
  • Local Institution - 0040
    Código postal verificado
    Bellflower, United States· Aún no reclutando
  • Local Institution - 0188
    Código postal verificado
    Chino, United States· Aún no reclutando
  • Local Institution - 0032
    Código postal verificado
    Culver City, United States· Aún no reclutando
  • Local Institution - 0037
    Código postal verificado
    Garden Grove, United States· Aún no reclutando
  • Local Institution - 0068
    Código postal verificado
    La Habra, United States· Aún no reclutando
  • Local Institution - 0128
    Código postal verificado
    Lemon Grove, United States· Aún no reclutando
  • Local Institution - 0187
    Código postal verificado
    Montclair, United States· Aún no reclutando

Preguntas comunes

What is KarXT?

KarXT is a new medicine being tested to see if it can help prevent symptoms of schizophrenia from returning.

¿Qué es un placebo?

A placebo is a 'dummy pill' that looks like the real medicine but doesn't contain any active ingredients. It's used to compare against the new medicine.

Will I know if I'm getting the real medicine?

No, neither you nor your study doctor will know if you're receiving KarXT or the placebo. This helps ensure the study results are fair and unbiased.

¿Cuánto tiempo estaré en el estudio?

The full duration of your participation will be explained by the study team, including how long you'll take the medicine and how many follow-up visits there will be.

¿Puedo abandonar el estudio si cambio de opinión?

Yes, you are free to leave the study at any time, for any reason, without it affecting your regular medical care.

Cómo obtener más información

Centro de Contacto de Ensayos Clínicos de BMS www.BMSClinicalTrials.com

Siempre hable con su médico de cabecera o especialista antes de decidir participar en un estudio.

¿Interesado en participar?

Registra tu interés

Comparte tus detalles y el equipo de investigación para "Relapse Prevention Trial Evaluating KarXT Treatment in Schiz…" se pondrá en contacto contigo si puedes ser elegible. Siempre habla con tu médico antes de aceptar participar.

Discusión

Discusión comunitaria

Impulsado por nuestro foro en community.patient.info. Por favor, sea respetuoso — esto no es un consejo médico.